CRISPR lets scientists find one specific sentence in three billion letters of DNA, cut it, and let the cell rewrite it. This page explains how, step by step, and what it is already being used for.
Every cell in your body carries a long instruction manual written in a four-letter alphabet: A, T, C and G. The manual is about 3 billion letters long. Stretches of it, called genes, are recipes for proteins, the molecular machines that do almost everything a cell does.
DNA is two strands wound around each other. The strands are not identical; they are complementary. Wherever one strand has an A, the other has a T. Wherever one has a C, the other has a G. That pairing rule is the whole reason CRISPR works: if you know one strand, you know the other, and you can build a short molecule that will stick to exactly one place.
A single wrong letter can matter. Sickle cell disease, for example, comes from one changed letter in the recipe for haemoglobin, the protein that carries oxygen in red blood cells.
CRISPR was not invented. It was found. Bacteria are attacked by viruses, and over billions of years they evolved an immune system that remembers past infections.1 The awkward name, Clustered Regularly Interspaced Short Palindromic Repeats, just describes what that memory looks like in the bacterium's DNA: a row of stored snippets of viral DNA, separated by repeated spacer sequences.
The system works in three moves.
The leap that won the 2020 Nobel Prize in Chemistry was realising that move three could be pointed at anything. Emmanuelle Charpentier, studying the bacterium Streptococcus pyogenes, discovered a previously unknown RNA molecule (tracrRNA) that is part of this defence. In 2011 she began working with Jennifer Doudna; together they rebuilt the system in a test tube, simplified it, and showed it could be reprogrammed to cut any DNA at a chosen site.1 The Nobel committee called it "genetic scissors".
The most common version of the tool, CRISPR-Cas9, has only two components.2
Cas9 is a protein. Think of it as a machine with two jobs: read DNA, and cut it. On its own it is aimless. It cannot choose where to cut.
The guide RNA is a short molecule, about 100 letters long, that snaps into Cas9. Twenty of those letters are the address. Because of the pairing rule from the previous section, a 20-letter address written in RNA will stick to exactly one 20-letter stretch of DNA that complements it. Change the 20 letters and you change where Cas9 cuts. That is the entire programming step.
One more rule matters. Cas9 will only bind and cut if the target is sitting right next to a short signature in the DNA called a PAM. For the Cas9 most labs use, that signature is any letter followed by two Gs, written NGG.3 Without a PAM, even a perfect 20-letter match is ignored.4 The PAM is also how the system avoids cutting the bacterium's own stored memories: the snippets in the CRISPR array have no PAM beside them.
Step through it below. The DNA is shortened so it fits on screen: a real address is 20 letters, this one is 12. Everything else follows the real mechanism, including the decoy stop, the unzipping, and where the cut lands.
NGG shows up every few dozen letters across the genome, so Cas9 stops at a PAM constantly. At each stop it bends and partially unwinds the DNA, pulling a few letters out so the guide can test them.5 Matching starts at the PAM end and works outward; if the first letters fail, Cas9 lets go within a fraction of a second and moves on.4 Only a site where all the letters pair up triggers the cutting machinery. Most of Cas9's life is spent rejecting near-misses.
When the match is complete, Cas9 cuts both strands at the same place, three letters away from the PAM.6 That produces a clean break straight through the double helix. Cas9 itself has now done its whole job. What happens next is up to the cell.
This is the part most explanations skip, and it is where the actual editing happens. Cas9 does not edit anything; it only breaks. Cells treat a double-strand break as an emergency and repair it within hours, using one of two systems.67
The default. Repair proteins grab the two loose ends and glue them back together. It is quick and sloppy: a few letters are often lost or added at the seam. Inside a gene, that usually shifts the reading frame, the way deleting one letter from "the cat ate the rat" gives "hec ata tet her at". The recipe becomes gibberish and the gene stops working. If your goal is to switch a gene off, this sloppiness is exactly what you want.
If a matching piece of DNA is nearby, the cell can use it as a reference and copy from it while repairing. Scientists exploit this by supplying a template that matches the surroundings of the cut but carries the change they want: a corrected letter, or a new segment. The cell copies the change in. This is precise, but it works less often than patching, and mostly in cells that are actively dividing.7
Cutting both strands is powerful but blunt. Since 2016, researchers have built variants of Cas9 that keep the address-finding ability but swap the scissors for something gentler.89
Finds the address, cuts both strands, hands the problem to the cell's repair crew. Best for disabling a gene.
A disabled Cas9 carrying a chemical that rewrites one letter in place (C to T, or A to G) without breaking the strands. No cut, so no sloppy repair. Limited to those swaps.8
A Cas9 that nicks one strand and carries its own writing template. It can make any single-letter change plus small insertions and deletions.9
Everything below is dated and sourced, because this field moves fast. As of September 2026:
Charpentier reports tracrRNA; with Doudna she rebuilds and reprograms the cutting system in a test tube.1 Labs worldwide adopt it within months.
The Royal Swedish Academy of Sciences awards the two of them the Nobel Prize in Chemistry "for the development of a method for genome editing".1
The UK's medicines regulator approves Casgevy, the first CRISPR-based medicine, for sickle cell disease and transfusion-dependent beta thalassaemia.10
The US FDA approves Casgevy for sickle cell disease in patients 12 and older with recurrent pain crises.1011 How it works: a patient's blood stem cells are removed, Cas9 is used to disable a switch that normally turns off fetal haemoglobin after birth, and the edited cells are returned after high-intensity chemotherapy clears space for them. Fetal haemoglobin doesn't sickle, so the crises stop.12
FDA approval extended to transfusion-dependent beta thalassaemia.11
KJ Muldoon, an infant with an ultra-rare liver enzyme deficiency, receives the first CRISPR therapy designed for a single patient, built by Children's Hospital of Philadelphia and Penn Medicine using base editing. The case was announced in May 2025; as of early 2026 he was walking with mild symptoms of a previously fatal condition.1314
The FDA announces a regulatory pathway aimed at individualised gene-editing therapies, and teams at the Innovative Genomics Institute prepare a second bespoke case.1516
FDA extends Casgevy to patients as young as 2.12
Crops: base editing has been used for herbicide-tolerant rice, improved rice grain quality, and nutritional changes in tomato, maize and wheat.8 Research: CRISPR is now a routine tool for switching genes off in cell lines and animals to learn what they do, and a "dead" Cas9 that binds without cutting is used to turn genes up or down and even to light up specific DNA regions under a microscope.9
Delivery. Cas9 and its guide are large molecules, and getting them into the right cells inside a living person is the hardest unsolved problem. Casgevy sidesteps it by editing cells outside the body. Editing the liver works because the liver naturally collects the lipid particles used to carry the editor. Most other tissues are still out of reach.9
Off-target cuts. A near-match with one or two wrong letters can occasionally still be cut. Guides are now designed by software to avoid this, and higher-fidelity Cas9 variants exist, but it has to be checked for every new therapy.8
Repair is not fully controllable. Template-based repair is inefficient, and end joining is random by nature. Base and prime editors exist largely to route around this.
Cost and access. Casgevy is a one-time treatment, but it requires a stem-cell transplant procedure and specialist centres.11
Every factual claim above traces to one of these. Where the text summarises a paper, follow the link for the original wording.